Abstract: Disclosed is a protein aqueous suspension preparation containing a protein and a polyamino acid, the protein and the polyamino acid having a surface charge in a buffer and forming a complex suspended in the buffer, wherein the absolute value of the difference between pH of the buffer and isoelectric point pI of the protein is in the range of from 0.5 to 4.0. Also disclosed are a method of preparing a protein aqueous suspension preparation and a prefilled syringe containing a concentrated protein aqueous suspension preparation. The protein can exhibit at least one of shaking stress resistance, fluidity enhancement, oxidation resistance, thermal stability, and aggregation inhibitory properties.

Abstract: Disclosed is a protein aqueous suspension preparation containing a protein and a polyamino acid, the protein and the polyamino acid having a surface charge in a buffer and forming a complex suspended in the buffer, wherein the absolute value of the difference between pH of the buffer and isoelectric point pI of the protein is in the range of from 0.5 to 4.0. Also disclosed are a method of preparing a protein aqueous suspension preparation and a prefilled syringe containing a concentrated protein aqueous suspension preparation. The protein can exhibit at least one of shaking stress resistance, fluidity enhancement, oxidation resistance, thermal stability, and aggregation inhibitory properties.

Abstract: A pharmaceutical composition containing urokinase and a physiological absorption enhancer comprising higher fatty acids, a polyalkylene glycol and calcium is disclosed. Whereas urokinase which is decomposed and inactivated in the stomach and is poorly absorbed from the intestinal tract cannot be orally administered, it can be orally administered in the form of the present composition by applying an enteric coating, because urokinase in the composition is highly absorbable from the intestinal tract. It is desirable in the present composition in view of the stability and sustained absorbability that urokinase is contained in said composition in the form of a liposome preparation in which the urokinase is incorporated in voids of the liposome. The components are incorporated in the present composition at a ratio of 0.01-2 mg. of the higher fatty acid, 0.01-5 mg. of the polyalkylene glycol and 0.0001-0.1 mg. of the calcium per 100 units of urokinase.